Mitral valve replacement with Alvarez prosthesis: long-term results

Y. A. S. MASHHOUR, J. B. GARCIA, M. IONESCU, AND G. H. WOOLER

From the General Infirmary, Leeds

The high mortality and morbidity that follow insertion of the Alvarez valve in the mitral position, and particularly the thrombo-embolic complications, stopped us from using it clinically in the Leeds General Infirmary.

Since the introduction of the Alvarez mitral valve prosthesis in 1964 it has been used clinically in Leeds General Infirmary because it was thought that it would produce better haemodynamic results than the other prosthetic valves.

The aim of this study is to present the long-term results in patients who had this prosthesis inserted in the mitral valve position, and to show the high incidence of thrombo-embolic manifestations.

CLINICAL MATERIAL

Since 25 August 1964 the Alvarez prosthetic valve has been inserted in the mitral position in 29 patients. This group of totally unselected patients had a mixed mitral valve lesion. They were 17 women and 12 men aged between 11 and 52 years, average age 36 years. Some of these patients had associated aortic or tricuspid valvular disease (Table I). Two had aortic incompetence, which was thought to be mild when the tricuspid valve was performed at the time the mitral valve was replaced.

Calcification was present in 19 of the 29 patients. All the 29 patients had severe disease of the chordae tendineae, so that none of the valves was suitable for repair.

The operative technique was the same in all patients, using the Melrose machine for extracorporeal circulation, combined with mild hypothermia to 33° or 34°C. The heart was fibrillated electrically on full perfusion. Tracheostomy at the end of the operation was performed only when necessary.

All the patients were anticoagulated on the fifth post-operative day.

RESULTS

Out of the 29 patients mentioned above, 14 are still alive. The time and cause of death of the 15 deceased patients is given in Tables III, IV, V, and VI respectively.

Considering Table VI, in patient 1 there is conclusive evidence that clotting occurred on the valve, necessitating re-operation to remove that

\[\text{Table II}\]

<table>
<thead>
<tr>
<th>Type of Previous Operation</th>
<th>No. of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitral valve repair</td>
<td>1</td>
</tr>
<tr>
<td>Transventricular closed mitral valvotomy</td>
<td>1—one valvotomy</td>
</tr>
<tr>
<td>Mitral valve exploration with finger (not suitable to proceed with valvotomy)</td>
<td>2</td>
</tr>
</tbody>
</table>

\[\text{Table I}\]

<table>
<thead>
<tr>
<th>Associated Lesion</th>
<th>No. of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aortic incompetence</td>
<td>2</td>
</tr>
<tr>
<td>Aortic incompetence and mixed tricuspid valve lesion</td>
<td>1</td>
</tr>
<tr>
<td>Aortic stenosis</td>
<td>1</td>
</tr>
<tr>
<td>Tricuspid incompetence</td>
<td>5</td>
</tr>
</tbody>
</table>
Cardiac arrest

Operative death (within 2 weeks of operation) 8
Hospital death (from 2-6 weeks) ... 1
Late mortality (after 6 weeks) ... 6

TABLE IV
OPERATIVE MORTALITY

<table>
<thead>
<tr>
<th>Cause of Death</th>
<th>Post-mortem Examination of Relevance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary oedema ...</td>
<td>Pulmonary oedema and pulmonary fat embolism</td>
</tr>
<tr>
<td>Pulmonary oedema and low cardiac output</td>
<td>Outflow tract obstruction demonstrated</td>
</tr>
<tr>
<td>Acute cardiac failure</td>
<td>Lung congestion and liver infarct</td>
</tr>
<tr>
<td>Acute cardiac failure.</td>
<td>Brain softening. Infarct of corpus callosum roof of the lateral ventricle on each</td>
</tr>
<tr>
<td>Brain damage</td>
<td>side; infarction of right cerebellar hemisphere</td>
</tr>
<tr>
<td>Acute cardiac failure.</td>
<td>Cerebellar infarct</td>
</tr>
<tr>
<td>Brain damage</td>
<td>Evidence of outflow tract obstruction, lung congestion, hyperaemia right parietal</td>
</tr>
<tr>
<td>Ventricular fibrillation</td>
<td>lobe</td>
</tr>
<tr>
<td>Cardiac arrest (metabolic disturbance)</td>
<td>Nothing of any relevance</td>
</tr>
<tr>
<td>On table from uncontrollable haemorrhage</td>
<td>Ruptured myocardium; the rigid vent used to keep the valve incompetent perforated the very thin ventricular wall.</td>
</tr>
</tbody>
</table>

TABLE V
HOSPITAL MORTALITY

<table>
<thead>
<tr>
<th>Cause of Death</th>
<th>Post-mortem Examination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac arrest 1 month after operation</td>
<td>Moderately severe aortic stenosis</td>
</tr>
</tbody>
</table>

TABLE VI
LATE MORTALITY

<table>
<thead>
<tr>
<th>Patient</th>
<th>Cause of Death</th>
<th>Post-mortem Examination of Relevance</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Cardiac arrest after re-operation to extract clot from Alvarez prosthesis 4 months after insertion</td>
<td>An old infarct in right frontal lobe and left insula</td>
</tr>
<tr>
<td>2</td>
<td>Cardiac failure 1-5 years post-op. in hospital while being prepared for second operation to replace the Alvarez which became incompetent. Patient developed 2 attacks of cerebral embolism. Right hemiplegia in hospital</td>
<td>Not done</td>
</tr>
<tr>
<td>3</td>
<td>Brain damage and secondary haemorrhage</td>
<td>Cerebral infarction (anticoagulants stopped because he developed torrential haemorrhage from a duodenal ulcer)</td>
</tr>
<tr>
<td>4</td>
<td>Brain damage (embolism)</td>
<td>Not done</td>
</tr>
<tr>
<td>5, 6</td>
<td>Died at home—not known</td>
<td></td>
</tr>
</tbody>
</table>

Until the present time only six patients out of the 29 operated upon are free from thromboembolic manifestation.

COMPLICATIONS In the group of survivors a multitude of complications developed either immediately or late after the operation. Thromboembolism proved to be the commonest and the most important. The following other complications are mentioned in order of their occurrence after the time of the operation:

Low cardiac output
2 patients

Pulmonary oedema
1 patient

Post-perfusion syndrome
1 patient

Pleural effusion
2 patients

to replace the Alvarez valve with a heterograft in 1967. While she was in hospital on full anticoagulant therapy she had two separate cerebral emboli which produced a right hemiplegia. While awaiting recovery from her cerebral condition she developed cardiac failure which did not respond to medical treatment, and she passed into liver failure and death.

Patient 3 (Table VI) developed torrential haemorrhage from a duodenal ulcer and anticoagulants had to be stopped. Immediately afterwards he developed a cerebral embolus and died in hospital.

Patient 4 also died one year after operation from a cerebral embolus which produced a right hemiplegia.

Both patients 5 and 6 (Table VI) died suddenly at home, presumably due to cerebral emboli, because their hearts were good and indeed they were more or less symptomless before they died. All patients were found to be grade IIB preoperatively when their exercise tolerance was assessed. Their exercise tolerance grading after operation is shown in Table VII.

Until the present time only six patients out of the 29 operated upon are free from thromboembolic manifestation.
Mitral valve replacement with Alvarez prosthesis: long-term results

Cardiac tamponade
  1 patient
Chest infection
  Bronchopneumonia
    1 patient
  Persistent bronchitis
    1 patient
Heart failure
  1 patient
Persistent auricular fibrillation
  1 patient (in sinus rhythm pre-operatively)
Subacute bacterial endocarditis
  2 patients
Serious anaemia
  1 patient
Tracheal stenosis
  1 patient
Thrombo-embolic manifestations
  Early
    1 patient (cerebral and renal)
  Late
    7 patients (All were cerebral. One has a complete personality change which is persistent. The remaining six patients had more or less transient attacks of hemiplegia, hemiparesis, aphasia, homonymous hemianopia, etc.)

DISCUSSION

In this group of 29 patients who had replacement of the mitral valve with an Alvarez valve prosthesis, the total mortality rate was 51.7%.

Of the survivors 57.3% developed thrombo-embolic complications. There were no immediate cerebral lesions following surgery which could have been caused by air or calcium during the operation. It is right to assume that the last two patients mentioned in Table VI died from cerebral emboli, so the total percentage of thromboembolism in this series of patients operated upon is 62.1%.

Table VIII compares the thrombo-embolic rate of other prosthetic valves with that of the Alvarez.

<table>
<thead>
<tr>
<th>Type of Prosthesis</th>
<th>No. of Patients</th>
<th>No. of Thrombo-embolic Complications</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starr-Edwards (Mayo clinic)</td>
<td>166</td>
<td>54</td>
<td>32.5</td>
</tr>
<tr>
<td>Mono-cusp (Mayo clinic)</td>
<td>35</td>
<td>6</td>
<td>17.1</td>
</tr>
<tr>
<td>Alvarez (Leeds General Infirmary)</td>
<td>29</td>
<td>16</td>
<td>62.1</td>
</tr>
</tbody>
</table>

The rate is very high for the Alvarez prosthesis and we believe that it is due to clot forming on the hinge joint mechanism (Figure). We therefore ceased to use this prosthesis after February 1967 because we were unable to prevent systemic emboli with full anticoagulant control.

Figure Photograph and artist's sketch of clot forming over the Alvarez prosthetic valve.

Starr, Herr, and Wood (1967) report an embolic rate of 43% using the old type of mitral valve prosthesis on 597 patients from 1960 to 1965. However, from 1965 to 1967, using the extended cloth prosthesis on 151 patients, only one embolus occurred. All patients have been maintained on anticoagulant therapy. Only recently have we commenced in Leeds to use the new extended cloth prosthesis.
I should like to thank Miss Beryl Walsh for the photograph and Miss Mary Brown for the artist’s sketch.

BIBLIOGRAPHY


Mitral valve replacement with Alvarez prosthesis: long-term results
Y. A. S. Mashhour, J. B. Garcia, M. Ionescu and G. H. Wooler

Thorax 1969 24: 287-290
doi: 10.1136/thx.24.3.287

Updated information and services can be found at:
http://thorax.bmj.com/content/24/3/287

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/